EZH2 and epithelioid sarcoma: Tazemetostat, a EZH2 inhibitor that has shown to be active in epithelioid sarcoma (EpS) [56], has been also investigated in other solid tumors harboring alterations in EZH2 or the SWI/SNF complex.